KDM1A and Cognitive impairment: Moreover, the role of KDM1A in schizophrenia is the rationale for EVOLUTION, an adaptive double‐blind placebo‐controlled phase IIb trial in schizophrenia,48 with multiple end points including improvement in negative symptoms and in cognitive impairment associated with schizophrenia.